WO2007117314A3 - Procédés et formulations permettant de préparer une forme dosifiée à libération contrôlée à administrer par voie orale - Google Patents

Procédés et formulations permettant de préparer une forme dosifiée à libération contrôlée à administrer par voie orale Download PDF

Info

Publication number
WO2007117314A3
WO2007117314A3 PCT/US2006/061625 US2006061625W WO2007117314A3 WO 2007117314 A3 WO2007117314 A3 WO 2007117314A3 US 2006061625 W US2006061625 W US 2006061625W WO 2007117314 A3 WO2007117314 A3 WO 2007117314A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
bupropion
making
pharmaceutical
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/061625
Other languages
English (en)
Other versions
WO2007117314A2 (fr
Inventor
San-Laung Chow
David Wong
Damian Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biokey Inc
Original Assignee
Biokey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/295,995 external-priority patent/US20060099262A1/en
Priority claimed from US11/295,851 external-priority patent/US20060099261A1/en
Application filed by Biokey Inc filed Critical Biokey Inc
Priority to CN200680046024.4A priority Critical patent/CN101453990B/zh
Publication of WO2007117314A2 publication Critical patent/WO2007117314A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007117314A3 publication Critical patent/WO2007117314A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Des modes de réalisation de l'invention concernent généralement des compositions médicamenteuses pharmaceutiques, des procédés de préparation de compositions médicamenteuses à administrer par voie orale, notamment des compositions dosifiées à libération prolongée, et des procédés destinés à traiter un patient sous traitement d'antidépresseurs ou un patient qui arrête de fumer. Dans un aspect de l'invention, l'invention concerne une formulation pharmaceutique comprenant un noyau renfermant du bupropion et ses dérivés formant sel, ainsi qu'un enrobage. L'enrobage peut comprendre au moins un agent tensio-actif et des dispersions aqueuses d'au moins un polymère insoluble pharmaceutiquement acceptable. Le noyau peut également comprendre des dispersions aqueuses d'au moins un polymère insoluble pharmaceutiquement acceptable. Dans un autre aspect, l'invention concerne des procédés destinés à préparer et à administrer une composition pharmaceutique se présentant sous une forme dosifiée à administrer par voie orale, notamment un comprimé.
PCT/US2006/061625 2005-12-06 2006-12-05 Procédés et formulations permettant de préparer une forme dosifiée à libération contrôlée à administrer par voie orale Ceased WO2007117314A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200680046024.4A CN101453990B (zh) 2005-12-06 2006-12-05 丁氨苯丙酮可控释放配方及其制造方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/295,995 US20060099262A1 (en) 2004-11-08 2005-12-06 Methods and formulations for making controlled release oral dosage form
US11/295,851 2005-12-06
US11/295,851 US20060099261A1 (en) 2004-11-08 2005-12-06 Methods and formulations for making controlled release oral dosage form
US11/295,995 2005-12-06

Publications (2)

Publication Number Publication Date
WO2007117314A2 WO2007117314A2 (fr) 2007-10-18
WO2007117314A3 true WO2007117314A3 (fr) 2008-08-07

Family

ID=38581526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/061625 Ceased WO2007117314A2 (fr) 2005-12-06 2006-12-05 Procédés et formulations permettant de préparer une forme dosifiée à libération contrôlée à administrer par voie orale

Country Status (1)

Country Link
WO (1) WO2007117314A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023285977A1 (fr) * 2021-07-14 2023-01-19 Zydus Lifesciences Limited Compositions pharmaceutiques d'ozanimod

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US20060099260A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US20060099260A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion

Also Published As

Publication number Publication date
WO2007117314A2 (fr) 2007-10-18

Similar Documents

Publication Publication Date Title
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007100614A3 (fr) FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE
WO2008002245A3 (fr) Nouveaux composés 385
WO2004062577A3 (fr) Utilisation d'un melange de deux ou de plusieurs materiaux enteriques afin de reguler la liberation de medicaments via une membrane ou une matrice dans des therapies systemiques
WO2007149406A3 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2007103557A3 (fr) Revêtement de capsules avec des ingrédients pharmaceutiques actifs
WO2007103200A3 (fr) Formulation orale à libération contrôlée pour des agents sédatifs ou hypnotiques
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
WO2007048219A3 (fr) Composition medicamenteuse a liberation prolongee
WO2007093880A3 (fr) Nouveaux dérivés d'indolopyrone et leur procédé de préparation
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
WO2006025070A3 (fr) Nebivolol et ses sels pharmaceutiquement acceptables, procede de preparation et compositions pharmaceutiques de nebivolol
WO2007009806A3 (fr) Formulations posologiques solides de medicaments narcotiques presentant une adsorption buccale amelioree
WO2008003050A3 (fr) Formulations de nitrate de gallium
MX341015B (es) Forma de dosificacion de liberacion extendida.
WO2009032843A3 (fr) Aminoalcools substitués
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
WO2005065639A3 (fr) Nouvelles compositions pharmaceutiques
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
WO2009084041A3 (fr) Compositions pharmaceutiques de dexibuprofène
WO2010044097A3 (fr) Nouvelle forme pharmaceutique de palipéridone et procédé de préparation de celle-ci
MY145581A (en) Combination of ferroquine and an artemisinin derivative for the treatment of malaria
WO2006061700A3 (fr) Compositions au gout masque et a desintegration rapide, et leurs procedes de preparation
WO2008004100A3 (fr) Composés thérapeutiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680046024.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06850878

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06850878

Country of ref document: EP

Kind code of ref document: A2